Omeros Other Long-Term Assets 2010-2025 | OMER

Omeros other long-term assets from 2010 to 2025. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Omeros Annual Other Long-Term Assets
(Millions of US $)
2024 $125
2023 $140
2022 $124
2021 $141
2020 $1
2019 $1
2018 $1
2017 $6
2016 $6
2015 $11
2014 $1
2013 $1
2012 $1
2011 $0
2010 $0
2009 $0
Omeros Quarterly Other Long-Term Assets
(Millions of US $)
2025-03-31 $123
2024-12-31 $125
2024-09-30 $131
2024-06-30 $134
2024-03-31 $137
2023-12-31 $140
2023-09-30 $121
2023-06-30 $117
2023-03-31 $121
2022-12-31 $124
2022-09-30 $145
2022-06-30 $128
2022-03-31 $135
2021-12-31 $141
2021-09-30 $1
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $1
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $6
2018-06-30 $6
2018-03-31 $6
2017-12-31 $6
2017-09-30 $6
2017-06-30 $6
2017-03-31 $6
2016-12-31 $6
2016-09-30 $11
2016-06-30 $11
2016-03-31 $11
2015-12-31 $11
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.181B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $232.407B 27.95
Boston Scientific (BSX) United States $155.727B 38.99
Stryker (SYK) United States $146.049B 30.54
EssilorLuxottica (ESLOY) France $127.608B 0.00
Medtronic (MDT) Ireland $106.425B 15.09
Haleon (HLN) United Kingdom $51.105B 29.10
Lonza Group Ag (LZAGY) Switzerland $50.009B 0.00
ResMed (RMD) United States $35.893B 26.96
GE HealthCare Technologies (GEHC) United States $32.299B 15.34
Agilent Technologies (A) United States $31.909B 20.73
Terumo (TRUMY) Japan $27.168B 35.29
Insulet (PODD) United States $22.874B 89.79
Koninklijke Philips (PHG) Netherlands $21.656B 15.57
Zimmer Biomet Holdings (ZBH) United States $18.236B 11.71
Baxter (BAX) United States $15.652B 11.69
Smith & Nephew SNATS (SNN) United Kingdom $12.683B 0.00
Sunny Optical Technology (SNPTF) China $9.032B 0.00
Demant (WILYY) Denmark $8.637B 0.00
Bio-Rad Laboratories (BIO) United States $6.175B 21.49
Lantheus Holdings (LNTH) United States $5.228B 13.19
Prestige Consumer Healthcare (PBH) United States $4.233B 18.91
Perrigo (PRGO) Ireland $3.680B 9.33
Shandong Weigao Medical Polymer (SHWGF) China $3.459B 0.00
ICU Medical (ICUI) United States $3.319B 24.48
Haemonetics (HAE) United States $3.253B 14.82
Envista Holdings (NVST) United States $3.097B 25.73
GN Store Nord (GNNDY) Denmark $2.224B 18.42
QuidelOrtho (QDEL) United States $2.074B 14.27
LeMaitre Vascular (LMAT) United States $1.857B 41.51
AtriCure (ATRC) United States $1.711B 0.00
Acuren (TIC) United States $1.276B 0.00
Neogen (NEOG) United States $1.272B 16.28
AdaptHealth (AHCO) United States $1.212B 12.30
Kestra Medical Technologies (KMTS) United States $1.156B 0.00
Green Thumb Industries (GTBIF) United States $1.109B 24.95
BioLife Solutions (BLFS) United States $1.039B 0.00
Phibro Animal Health (PAHC) United States $0.990B 12.65
InMode (INMD) Israel $0.927B 9.34
CeriBell (CBLL) United States $0.608B 0.00
Evolus (EOLS) United States $0.593B 0.00
Maravai LifeSciences Holdings (MRVI) United States $0.573B 0.00
Curaleaf Holdings (CURLF) Canada $0.550B 0.00
Valneva SE (VALN) France $0.535B 0.00
Owens & Minor (OMI) United States $0.510B 4.23
Capricor Therapeutics (CAPR) United States $0.452B 0.00
Tilray Brands (TLRY) Canada $0.428B 0.00
Surmodics (SRDX) United States $0.415B 0.00
SEMPERIT AG HLD (SEIGY) Austria $0.366B 0.00
SNDL (SNDL) Canada $0.334B 0.00
VAREX IMAGING (VREX) United States $0.316B 11.62
Aurora Cannabis (ACB) Canada $0.298B 53.00
Cresco Labs (CRLBF) United States $0.295B 0.00
Viemed Healthcare (VMD) United States $0.263B 22.17
Sanara MedTech (SMTI) United States $0.258B 0.00
ZimVie (ZIMV) United States $0.255B 11.57
Cerus (CERS) United States $0.243B 0.00
Canopy Growth (CGC) Canada $0.243B 0.00
Verano Holdings (VRNOF) United States $0.229B 0.00
Sanuwave Health (SNWV) United States $0.224B 0.00
OraSure Technologies (OSUR) United States $0.215B 0.00
Quanterix (QTRX) United States $0.202B 0.00
Brainsway (BWAY) Israel $0.193B 51.00
Biote (BTMD) United States $0.189B 5.32
TriSalus Life Sciences (TLSI) United States $0.189B 0.00
High Tide (HITI) Canada $0.182B 0.00
Organigram Global (OGI) Canada $0.181B 0.00
Utah Medical Products (UTMD) United States $0.179B 14.57
Exagen (XGN) United States $0.148B 0.00
FitLife Brands (FTLF) United States $0.137B 0.00
Jin Medical (ZJYL) China $0.118B 0.00
TerrAscend (TSNDF) Canada $0.107B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.096B 0.00
Fonar (FONR) United States $0.090B 11.60
Agape ATP (ATPC) $0.087B 0.00
MacroGenics (MGNX) United States $0.086B 0.00
Quipt Home Medical (QIPT) United States $0.078B 0.00
Veru (VERU) United States $0.074B 0.00
InterCure (INCR) Israel $0.071B 0.00
Zynex (ZYXI) United States $0.071B 0.00
Apyx Medical (APYX) United States $0.059B 0.00
Jushi Holdings (JUSHF) United States $0.059B 0.00
ImmuCell (ICCC) United States $0.058B 0.00
Cytosorbents (CTSO) United States $0.053B 0.00
United Health Products (UEEC) United States $0.052B 0.00
Modular Medical (MODD) United States $0.047B 0.00
United-Guardian (UG) United States $0.038B 13.18
Rockwell Medical (RMTI) United States $0.034B 0.00
Nephros (NEPH) United States $0.029B 38.86
Safety Shot (SHOT) United States $0.021B 0.00
Allurion Technologies (ALUR) United States $0.020B 0.00
INLIF (INLF) $0.017B 0.00
Flora Growth (FLGC) United States $0.015B 0.00
IM Cannabis (IMCC) Canada $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
Trinity Biotech (TRIB) Ireland $0.012B 0.00
Meihua Medical Technologies (MHUA) China $0.011B 0.00
Innovative Eyewear (LUCY) United States $0.010B 0.00
Senestech (SNES) United States $0.005B 0.00
GlucoTrack (GCTK) United States $0.004B 0.00
Akanda (AKAN) Canada $0.002B 0.00
Sharps Technology (STSS) United States $0.000B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.000B 0.00